Toframicin; The next-generation antibiotic

The next-generation aminoglycoside antibiotic

Toframicin is a semi-synthetic antibiotic which is in development for the treatment of hospital-acquired-/ventilator-associated pneumonia, bloodstream infections and neonatal sepsis.

Toframicin has ultra-broad spectrum activity, overcome drug class-related bacterial resistance, and offers an increased therapeutic window.

  • Antimicrobial compounds
  • Infection prevention
  • Antimicrobial stewardship
  • Microbial diagnostics
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Development
  • Research
  • Validation
  • Market entry
  • Marketed product

  • Company
  • Academia
  • Institute
  • NGO
  • Government

  • License
  • Co-develop
  • Outsource
  • Joint Venture
  • Sell

Funding organisation:

    Infectious disease area:

      Geographic origin:

        Multi-asset pharmaceutical companies focusing on anti-infective development.

        AGILeBiotics B.V. is a pre-clinical stage biotech company focusing on the development of novel antibiotics

        In addition, we are interested in developing Toframicin against MDR tuberculosis and lung infections associated with Cystic Fibrosis.

        What is going on with AMR?
        Stay tuned with remarkable global AMR news and developments!